Riverview Trust Company’s Amedisys AMED Stock Holding History

Riverview Trust Company’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9	Closed	-$817	–	604
2024 Q4	$817	Buy	+9	New	+$827	﹤0.01%	676

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Riverview Trust Company's AMED Position: Q1 2025 in Review

Riverview Trust Company sold out of Amedisys (AMED) in Q1 2025, closing a stake of 9 shares — an estimated $817 sold.

Riverview Trust Company first reported a position in AMED in Q4 2024 and held it in 1 quarter. The position peaked at $817 in Q4 2024. 304 funds tracked by Wall St. Rank hold AMED as of Q1 2025.

Riverview Trust Company reported no remaining Amedisys position as of Q1 2025 after selling out during the quarter.
Riverview Trust Company sold 9 Amedisys shares in Q1 2025, an estimated $817.
Riverview Trust Company first reported a position in Amedisys in Q4 2024 and held it in 1 quarter.
Riverview Trust Company's Amedisys position peaked at $817 in Q4 2024.
304 funds tracked by Wall St. Rank held Amedisys as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.